Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP2086 and Simvastatin Interaction Study
NCT02817243Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Mar 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retagliptin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SP2086 at Day 9, Maximum Plasma Concentration of SP2086 acid at Day 9 and 4 more. Status: unknown.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02817243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817243.